NASDAQ$RZLT
Rezolute Inc · Q3 2026 earnings
Q3 2026 earnings · · After market close
Briefing
Rezolute reported fiscal Q3 2026 net loss of $57.1M with no product revenue.
For the fiscal third quarter ended March 31, 2026, Rezolute reported a net loss of $57.1 million with no product revenue as leptin receptor programs advance in clinical development.
- Net loss $57.1M in fiscal Q3.
- Clinical-stage metabolic/rare disease focus.
- Elevated trial and personnel costs.
- Cash runway critical.
Headline financials
Revenue & EPS history
Rezolute Inc · Revenue · Quarterly
$0
Forward guidance
Clinical data and financing will determine path to commercialization.
Tailwinds
- Lead mechanism in underserved indications.
Headwinds
- High quarterly burn.
- No near-term revenue.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 3 quarterly earnings reports · overlaid with Q3 2026
+2.6%
Avg return
Earnings day
-0.8%
Avg return
5 days after
-12.5%
Avg return
30 days after
75%
3 / 4 earnings
Positive
+5.8%
Q2 2026
Best reaction
+0.0%
Q4 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q3 2026 | +0.3% | -1.8% | +20.5% | |
| Q2 2026 | +5.8% | -0.4% | -28.5% | |
| Q2 2021 | +4.4% | +3.8% | -44.8% | |
| Q4 2016 | +0.0% | -4.8% | +2.8% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro